Transmucosal Drug Delivery Systems Market Size, Share, Growth by 2030

The transmucosal drug delivery systems market was valued at US$ 80.21 billion in 2023 and is projected to reach US$ 129.46 billion by 2031, reflecting an estimated compound annual growth rate (CAGR) of 6.2% from 2023 to 2031.

Several key factors are propelling the growth of this market, notably the increasing adoption of drug delivery systems for effective disease management. Furthermore, the emergence of novel drug molecules and biological formulations is significantly contributing to the expansion of the market. However, challenges such as concerns regarding biocompatibility and a limited pool of drug candidates are hindering market progress.

Market Trends in Transmucosal Drug Delivery Systems

The integration of nanotechnology into transmucosal drug delivery systems is a notable trend, facilitating the creation of nanoscale drug carriers that enhance the physicochemical properties of drugs and enable targeted delivery to mucosal tissues. Various strategies have been proposed for the application of drug-loaded nanoparticles (NPs) onto the buccal mucosa for both local and systemic therapeutic effects. There is a growing interest in developing mucoadhesive buccal formulations, particularly those utilizing hydrogel composites that incorporate mucoadhesive films with NPs. For example, a review published by the Multidisciplinary Digital Publishing Institute (MDPI) in August 2020 highlighted the diverse applications of silica NPs in transmucosal drug delivery. The review concluded that silica nanoparticles are promising candidates as effective drug nanocarriers due to their ease of preparation, control over particle size and shape, high drug loading capacity, and ability to provide controlled drug release. By synthesizing various types of silica NPs with different functional groups, enhanced drug delivery efficacy can be achieved.

As a result, these technological advancements are expected to shape new trends in the drug delivery systems market in the forthcoming years.

Segmental Overview of the Transmucosal Drug Delivery Systems Market

The transmucosal drug delivery systems market is categorized based on systems and end users.

In terms of systems, the market is divided into nasopulmonary, buccal & sublingual, vaginal, and others. The nasopulmonary segment dominated the market share in 2023 and is projected to exhibit the highest CAGR during the period from 2023 to 2031. The buccal route of drug administration is a noninvasive, topical approach where drugs are placed in the buccal cavity, which is the area between the cheek and gums. Once absorbed through the oral mucosa, these drugs enter systemic circulation via the jugular vein, effectively bypassing the intestines. This method offers numerous advantages, including a rapid onset of action and enhanced bioavailability compared to the oral route. Additionally, it avoids first-pass metabolism, thereby protecting the drug from degradation in the gastrointestinal (GI) tract.

Regarding end users, the market is segmented into healthcare facilities, homecare settings, and others. The healthcare facilities segment accounted for the largest market share in 2023, driven by the availability of advanced facilities and skilled healthcare professionals in hospitals. Conversely, the homecare settings segment is expected to experience the highest CAGR from 2023 to 2031.

Geographical Overview of the Transmucosal Drug Delivery Systems Market

The geographical scope of the transmucosal drug delivery systems market report includes North America (comprising the US, Canada, and Mexico), Europe (including Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (covering South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), the Middle East & Africa (encompassing South Africa, Saudi Arabia, the UAE, and the Rest of the Middle East & Africa), and South & Central America (including Brazil, Argentina, and the Rest of South & Central America). In terms of revenue, North America held the largest market share in 2023, with the US being the dominant player in this region. This dominance can be attributed to the rising prevalence of chronic diseases such as diabetes, asthma, and cardiovascular conditions, along with an increasing number of product launches by leading industry players.

Transmucosal Drug Delivery Systems Market Size, Share, Growth by 2030

Market Trends in Transmucosal Drug Delivery Systems

Segmental Overview of the Transmucosal Drug Delivery Systems Market

Geographical Overview of the Transmucosal Drug Delivery Systems Market

TABLE OF CONTENTS

LIST OF TABLES

LIST OF FIGURES

Related Reports